Antiphospholipid Syndrome (APS)
17
8
10
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
5.9%
1 terminated out of 17 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (17)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
Hematological Disorders in EHPVO Patients
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
Effect of Belimumab on Antibody Titers in Primary APS Patients